Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,033 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD19-targeted CAR T cells in refractory antisynthetase syndrome.
Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, Reimann H, Taubmann J, Kretschmann S, Rösler W, Manger B, Wacker J, Mougiakakos D, Jabari S, Schröder R, Uder M, Roemer F, Krönke G, Mackensen A, Schett G. Müller F, et al. Among authors: schett g. Lancet. 2023 Mar 11;401(10379):815-818. doi: 10.1016/S0140-6736(23)00023-5. Epub 2023 Feb 15. Lancet. 2023. PMID: 36930673 No abstract available.
Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies.
Taubmann J, Knitza J, Müller F, Völkl S, Aigner M, Kleyer A, Gary R, Kretschmann S, Boeltz S, Atzinger A, Kuwert T, Roemer F, Uder M, Mackensen A, Schett G. Taubmann J, et al. Among authors: schett g. Rheumatology (Oxford). 2024 Jan 4;63(1):e12-e14. doi: 10.1093/rheumatology/kead330. Rheumatology (Oxford). 2024. PMID: 37432378 Free PMC article. No abstract available.
Tixagevimab/cilgavimab for the prevention of COVID-19 in vaccine-refractory patients with autoimmune diseases: a prospective cohort study.
Minopoulou I, Tascilar K, Corte G, Mutlu MY, Schmidt K, Bohr D, Hartmann F, Manger K, Manger B, Korn K, Kleyer A, Simon D, Harrer T, Schett G, Fagni F. Minopoulou I, et al. Among authors: schett g. Rheumatology (Oxford). 2024 May 2;63(5):1377-1383. doi: 10.1093/rheumatology/kead391. Rheumatology (Oxford). 2024. PMID: 37531288
Anti-CD19 CAR T cells for refractory myasthenia gravis.
Haghikia A, Hegelmaier T, Wolleschak D, Böttcher M, Desel C, Borie D, Motte J, Schett G, Schroers R, Gold R, Mougiakakos D. Haghikia A, et al. Among authors: schett g. Lancet Neurol. 2023 Dec;22(12):1104-1105. doi: 10.1016/S1474-4422(23)00375-7. Lancet Neurol. 2023. PMID: 37977704 No abstract available.
Comment on: Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T-cells after failure of several B cell depleting antibodies: reply.
Taubmann J, Knitza J, Müller F, Völkl S, Aigner M, Kretschmann S, Atzinger A, Kuwert T, Mackensen A, Schett G. Taubmann J, et al. Among authors: schett g. Rheumatology (Oxford). 2023 Dec 21:kead669. doi: 10.1093/rheumatology/kead669. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 38127905 No abstract available.
Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial.
Stephan M, Tascilar K, Yalcin-Mutlu M, Hagen M, Haschka J, Reiser M, Hartmann F, Kleyer A, Hueber AJ, Manger B, Figueiredo C, Cobra JF, Tony HP, Finzel S, Kleinert S, Wendler J, Schuch F, Ronneberger M, Feuchtenberger M, Fleck M, Manger K, Ochs W, Schmitt-Haendle M, Lorenz HM, Nüsslein H, Alten R, Henes J, Krüger K, Schett G, Rech J. Stephan M, et al. Among authors: schett g. J Clin Med. 2023 May 28;12(11):3723. doi: 10.3390/jcm12113723. J Clin Med. 2023. PMID: 37297917 Free PMC article.
1,033 results